OneSource Specialty Pharma: The $400M GLP-1 Fill-Finish Ambition

Executive Summary

OneSource Specialty Pharma Ltd. (NSE: ONESOURCE, BSE: 544292) has emerged as India’s inaugural pure-play, multimodal specialty pharmaceutical Contract Development and Manufacturing Organization (CDMO). Engineered through the strategic consolidation of Strides Pharma Science's soft gelatin capabilities, SteriScience's sterile injectables, and Stelis Biopharma's biologics platform, OneSource presents a highly differentiated value proposition within the global pharmaceutical supply chain.

The company is currently navigating a pivotal operational inflection point. Following a transient financial contraction in the third quarter of the 2026 financial year (Q3 FY26)—precipitated by regulatory deferrals in core North American markets—the organization has demonstrated a profound fundamental turnaround. Validated by the Q1 FY27 financial performance, which featured a 37% year-over-year revenue expansion and substantial margin accretion, the company's underlying operating leverage is becoming evident. Supported by an aggressive capital expenditure initiative exceeding $100 million, a dominant first-mover advantage in the Glucagon-like peptide-1 (GLP-1) fill-finish ecosystem, and a robust intellectual property foundation, OneSource is structurally optimized to capture disproportionate market share. The reiterated corporate guidance of achieving $400 million in organic revenue with a steady-state EBITDA margin of approximately 40% by FY28 highlights the management's high-conviction growth trajectory.

Corporate Lineage and Structural Metamorphosis

The architectural foundation of OneSource Specialty Pharma is rooted in over a decade of biotechnological and pharmaceutical evolution. The entity was originally incorporated on June 12, 2007, under the name Inbiopro Solutions Private Limited (Corporate Identification Number: L74140MH2007PLC432497), with its registered office situated in Navi Mumbai, Maharashtra. Initially conceptualized as an early-stage biotechnology research enterprise, Inbiopro was subsequently acquired and rebranded as Stelis Biopharma Limited, which functioned as a dedicated biologics development arm.

Recognizing the valuation premiums and operational synergies inherent in specialized, scaled contract manufacturing, the promoter group orchestrated a strategic decoupling of CDMO assets from their proprietary pharmaceutical operations. Stelis Biopharma was subsequently rechristened OneSource Specialty Pharma Ltd., designated as the apex holding and operating entity for a newly consolidated, multimodal platform.

The Composite Scheme of Arrangement

To achieve immediate global scale, technical depth, and a streamlined go-to-market strategy, OneSource executed a highly complex multi-entity Composite Scheme of Arrangement and Amalgamation pursuant to Sections 230 to 232 of the Indian Companies Act, 2013. The restructuring consolidated fragmented assets to reduce supply chain complexity for global biopharmaceutical partners, effectively bringing formulation, active pharmaceutical ingredient (API) handling, and aseptic fill-finish under a unified Quality Management System (QMS).

Having received clearance from the Securities and Exchange Board of India (SEBI) and "No Objection" letters from the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) on February 25, 2026, the scheme designated April 1, 2026, as the appointed date for the merger of the Indian entities. The consolidation involved sequential mergers by absorption:

• Steriscience Specialties Private Limited (SSPL): A holding entity engaged in sterile injectables through strategic investments, primarily absorbed into Brooks Steriscience Limited (BSL).
• Brooks Steriscience Limited (BSL): A backward-integrated manufacturer specializing in sterile penem formulations (specifically Carbapenems) located in Vadodara, Gujarat. Following the absorption of SSPL, BSL was merged directly into OneSource.
• Steriscience Pte Limited (Steriscience SG): A Singapore-domiciled entity housing the group's Abbreviated New Drug Applications (ANDAs) for the United States market and vital global intellectual property rights, alongside subsidiaries in the Netherlands and Poland. Its integration localized global commercial partnerships within OneSource.
• Strides Pharma Services Private Limited (SPSPL): Absorbed to seamlessly integrate legacy pharmaceutical service capabilities.

The amalgamation was underpinned by rigorous valuation frameworks conducted by PwC Business Consulting Services LLP and fairness opinions issued by ICICI Securities. Utilizing a relative valuation approach based on a "Going Concern" premise for operating entities and a Net Asset Value methodology for holding entities, the resulting share swap ratios dictated the equity restructuring.

This consolidation resulted in a fortified capitalization structure. Prior to its market debut on January 24, 2025, the enterprise secured equity commitments of ₹801 crore (approximately $95 million) from marquee investors at a pre-money valuation of $1.65 billion, providing the critical liquidity necessary to pursue aggressive capacity expansions.

Intellectual Property and Foundational Innovation

Beyond sheer manufacturing capacity, the foundational strength of OneSource is anchored in its proprietary research and intellectual property portfolio. Originating from its legacy as Inbiopro and Stelis, the company commands a specialized patent portfolio encompassing 18 total documents, with key grants emphasizing complex bioprocessing.

These patents validate the company's intrinsic capability to handle highly sensitive biomolecules, an expertise that translates directly into its competitive advantage in the peptide and biologics CDMO markets.

Multimodal Business Platforms and Technical Capabilities

OneSource’s strategic differentiation is its "multimodality" operating model. By housing distinct, technologically complex manufacturing platforms within a single corporate structure, the company serves as an end-to-end partner spanning early-stage development, clinical evaluation, regulatory submission, and commercial supply.

Drug-Device Combinations (DDCs) and the GLP-1 Paradigm

The paramount growth vector for OneSource is its Drug-Device Combination (DDC) platform. The global pharmaceutical landscape has been fundamentally altered by the advent of GLP-1 agonists, such as semaglutide and tirzepatide, indicated for Type-2 diabetes and obesity. The unprecedented patient demand for these therapies has created severe structural bottlenecks in the global supply chain, specifically in the complex aseptic fill-finish and precision pen-assembly stages.

OneSource has secured a first-mover advantage, establishing one of the largest and most advanced GLP-1 fill-finish infrastructures in India. The DDC solutions encompass formulation, highly precise cartridge filling utilizing premium Bausch & Strobel lines, sophisticated device assembly, analytical validation, and stability testing.

The company is executing an aggressive capacity scale-up to meet burgeoning global demand. The installed capacity of 40 million cartridges is undergoing a phased expansion, projected to reach 100 million by FY26, 140 million by FY27, and ultimately 220 million units by FY28. This is complemented by an existing capacity of 50 million Pre-Filled Syringes (PFS) and over 20 qualified assembly platforms capable of handling fixed-dose, variable-dose, pull-push pen systems, and advanced auto-injectors.

The commercial viability of this platform is evidenced by a robust pipeline of over 50 active DDC projects and contracts with approximately 20 global partners, including four of the top five global generic pharmaceutical corporations, encompassing seven of the eight major GLP-1 molecules. OneSource's execution capabilities were decisively proven during the launch of generic semaglutide in India (following patent expiration in March 2026), where the company supplied 10 out of the 21 generic pen brands available on day one, capturing over 40% of the domestic generic pen market share.

Internationally, OneSource serves as the critical manufacturing node for Dr. Reddy's Laboratories. Despite a temporary Canadian regulatory setback involving a Notice of Non-Compliance, the strategic partnership persevered, with Orbicular leading the product development and OneSource providing the end-to-end manufacturing framework that eventually supported Health Canada's approval and a subsequent launch planning phase. The company has also secured critical approvals from the Saudi Food and Drug Authority (SFDA) for generic semaglutide in Saudi Arabia and has partnered with Natco Pharma for First-To-File (FTF) submissions for Ozempic in the United States, illustrating a highly diversified geographic footprint.

The underlying economics of the DDC segment are highly favorable. Contracts are typically structured as "take-or-pay" Master Service Agreements (MSAs) that transition into high-margin Commercial Supply Agreements (CSAs) upon product approval. Given the extreme barriers to entry in peptide aseptic filling, this segment commands steady-state EBITDA margins approaching 50%. Analysts project the DDC business to generate up to $187 million (approximately ₹1,200 crore to ₹1,930 crore) by FY28, representing a sevenfold increase from FY24 levels.

Biologics: Mammalian and Microbial Ecosystems

The biologics CDMO sector requires vast capital and profound technical acumen. OneSource differentiates itself as a premier Asia-Pacific player by housing fully integrated Drug Substance (DS) and Drug Product (DP) capabilities for both microbial and mammalian expression systems within a single, unified campus.

The technological infrastructure supports a wide array of modalities, including recombinant proteins, monoclonal antibodies (mAbs), biosimilars, cell and gene therapies, and RNA-based products. The facilities deploy Chinese Hamster Ovary (CHO) cell lines for mammalian cell culture, scaling from 50L to 2,000L bioreactors, alongside Escherichia coli (E. coli) and Pichia platforms for microbial fermentation, scaling from 50L to 1,000L. To capture future demand, management has committed to doubling the total biologics capacity from the current 4kL to 8kL through high-ROI capital expenditures.

Commercial traction within the biologics division is accelerating, marked by a fourfold year-over-year increase in the Request for Proposal (RFP) funnel, comprising over 50 active engagements and 9 New Chemical Entity (NCE-1) and New Biological Entity (NBE) programs. The company recently onboarded a prominent United States-based biosimilar major possessing a pipeline of over five biosimilars and is in advanced discussions with several European entities. A hallmark achievement is the strategic manufacturing alliance with Munich-headquartered Formycon AG, aligning OneSource with Formycon's FYB4Growth strategy to provide integrated DS and DP manufacturing for complex biosimilars.

Strategically, the biologics segment is perfectly positioned to capitalize on macroeconomic tailwinds. As geopolitical tensions drive Western pharmaceutical companies to diversify supply chains away from historical hubs, the anticipated U.S. BIOSECURE Act incentivizes outsourcing to highly compliant Indian CDMOs, presenting OneSource with a generational opportunity to capture commercial-scale biologic manufacturing.

Complex Sterile Injectables

The sterile injectables division focuses on the formulation and aseptic production of advanced dosage forms, including liquid vials, lyophilized vials, and specialized high-potency antibiotics.

A core strength of this division is its dominance in the penicillin market, where OneSource ranks among the top five suppliers to the United States. The integration of Brooks Steriscience exponentially expanded this capability by adding a dedicated, USFDA-approved facility in Vadodara, Gujarat, designed specifically for the production of Meropenem and other potent Carbapenem injections.

To further scale operations and consolidate market share, OneSource is executing the acquisition of two additional USFDA-approved specialty injectable assets from Steriscience Specialties, anticipated to conclude by Q3 FY27. These assets are projected to contribute a combined revenue of $100 million with an EBITDA margin of approximately 40% by FY28, significantly augmenting the sterile platform's cash generation.

Oral Technologies: Soft Gelatin Capsules

Inherited from the legacy operations of Strides Pharma Science, the soft gelatin capsule (SGC) business provides OneSource with stable, foundational cash flows. Benefiting from over three decades of operational history, the division boasts an installed capacity of 2.4 billion capsules annually, establishing it as one of the top five softgel manufacturing capacities globally.

The technical parameters of this segment include sophisticated lipid-based drug delivery systems, solubility enhancement techniques, and high-volume manufacturing of diverse shapes and specialized formulations. The division is actively moving up the value chain, recently launching a specialized oncology product in partnership with a top 10 U.S. pharmaceutical company. Driven by new launches and capacity optimization, the softgel business is projected to achieve a 12.6% compound annual growth rate (CAGR) through the FY25–FY28 period.

Infrastructure, Manufacturing Network, and Quality Compliance

The operational architecture of OneSource is supported by a network of five state-of-the-art manufacturing facilities, predominantly clustered in Bengaluru, Karnataka—with specific sites in Venkatadri Layout, Obadenahalli (Doddaballapur 3rd Phase Industrial Area), and Bilekahalli (Bannerghatta Road)—complemented by the Vadodara facility. The company is actively pursuing expansion, noting that the Government of Karnataka has accorded in-principle approval for the Unit-II expansion project in Obadenahalli under the Karnataka Industrial Policy (KIP) 2025-30, unlocking valuable state incentives and concessions.

To operate these highly technical facilities, OneSource has scaled its human capital significantly. As of early 2026, the company employed a workforce of 1,672 professionals. Concurrently, human resource management has improved, reflected in a decline in the permanent employee turnover rate from 27% to 23% year-over-year, ensuring the retention of highly specialized technical talent.

Regulatory Compliance Track Record

In the CDMO sector, an unblemished regulatory record is the ultimate barrier to entry. OneSource maintains a stellar compliance history, having successfully cleared over 220 regulatory and customer audits. The manufacturing network holds accreditations from the world's most stringent regulatory authorities, including:

• United States Food and Drug Administration (USFDA)
• European Medicines Agency (EMA) and regional bodies such as the State Office for Occupational Safety, Schleswig-Holstein, Germany
• Health Canada
• Therapeutic Goods Administration (TGA) of Australia
• Agência Nacional de Vigilância Sanitária (ANVISA) of Brazil
• WHO GMP and the Medicines Control Council (MCC).

A defining validation of the company's Quality Management Systems occurred during a USFDA current Good Manufacturing Practices (cGMP) inspection at the Sterile Product Division (SPD) in Bilekahalli, Bengaluru. Conducted between June 22 and June 30, 2026, the inspection concluded with a single procedural observation—a highly favorable outcome that reinforces the facility's pristine compliance standing. Furthermore, the flagship DDC facility secured a critical cGMP certification from ANVISA in Q1 FY26, unlocking the pathway for commercial GLP-1 launches in the high-margin Brazilian market.

Financial Architecture and Operational Leverage

The financial narrative of OneSource encapsulates the structural dynamics of the CDMO industry: extreme revenue volatility linked to regulatory timelines, followed by massive non-linear margin expansion once commercial supply agreements commence and fixed costs are absorbed.

The Q3 FY26 Trough: Regulatory Deferrals and Fixed Cost Pressures

During the third quarter of the 2026 financial year (ending December 2025), OneSource experienced a severe financial dislocation. Consolidated revenue contracted by 26% year-over-year to ₹290.3 crore ($33.1 million), while operating profit (EBITDA) collapsed by 88% to a mere ₹17.3 crore ($2.0 million). This resulted in an EBITDA margin compression of over 3,000 basis points down to just 6%, culminating in a reported net loss of ₹88.7 crore (an adjusted PAT loss of ₹47.2 crore).

The contraction was primarily attributable to a structural timing mismatch rather than a loss of market share. A principal client (Dr. Reddy's Laboratories) faced regulatory delays from the Canadian Pharmaceutical Drugs Directorate regarding its generic semaglutide formulation, receiving a Notice of Non-Compliance that halted the transition of OneSource's contract from an MSA to a CSA phase.

Because high-containment CDMO facilities carry immense fixed overhead costs—including continuous cleanroom HVAC operations, specialized personnel, and rigorous quality assurance protocols—the deferral of revenue recognition resulted in a brutal negative operating leverage effect. Furthermore, the company made a strategic decision to hold semaglutide inventory (despite it being a customer risk) to maintain long-term partner relationships, while concurrently pausing the onboarding of new GLP-1 customers to reserve capacity for imminent commercial contracts. Financials were further suppressed by a full provision for the new wage code recognized entirely within the Q3 period.

This aggressive scaling and capital expenditure phase also strained working capital, evidenced by the recording of 281 delayed MSME payments (including entities such as Pharmonix Biologicals Pvt Ltd) during the mid-2025 period, a classic symptom of tightening liquidity during a transition phase.

The Q4 FY26 and Q1 FY27 Inflection: Operating Leverage Realized

As regulatory bottlenecks resolved and commercial production scaled, the financial architecture demonstrated a powerful V-shaped recovery, validating the underlying profitability of the DDC segment.

• Q4 FY26: The business rebounded with sequential revenue growth of 47% to ₹428.2 crore. EBITDA expanded over fivefold to ₹91.9 crore, pushing margins to 21.5% and allowing the company to return to a positive adjusted PAT of ₹39 crore. Despite this, the cumulative impact of the first half resulted in an FY26 standalone turnover of ₹1,420.4 crore but a consolidated net loss for the full year.
• Q1 FY27: Momentum accelerated dramatically. Consolidated revenue reached ₹449 crore (a 37% year-over-year increase), while EBITDA surged 39% year-over-year to ₹123.3 crore, driving EBITDA margins up by 600 basis points sequentially to 27.5%. Adjusted PAT grew 63% sequentially to ₹63.7 crore.

Notably, the standalone financial performance in Q1 FY27 revealed intense core profitability, generating ₹446.5 crore in revenue and ₹51.2 crore in PAT before group-level consolidation adjustments and scheme-related intangible amortizations. This recovery definitively illustrates that once the Bausch & Strobel lines commence commercial output, the absorption of fixed costs yields rapid margin accretion.

Financial Trajectory Synopsis

Note: Adjusted PAT and EPS exclude exceptional items and scheme-related intangible amortization (₹34.4 crore per quarter).

Capital Allocation, Debt, and Capex Strategy

To secure its competitive moat, OneSource is executing a massive capital expenditure program exceeding ₹700 crore (approximately $100 million) spanning the FY26-FY28 period. Over 80% of this capex is already committed, primarily directed toward the Phase 2 expansion of the flagship DDC facility (accelerating Line 1 installation for FY27 commercialization) and the 8kL biologics expansion.

Funding this expansion requires a sophisticated capital structure blending internal accruals, customer advances (reservation fees to secure future capacity), and structured debt. While total term debt temporarily escalated to ₹679 crore (and total debt excluding lease liabilities to ₹1,353 crore by December 2025), the company has maintained strict financial discipline. Benefiting from multiple credit rating upgrades into the 'A' family, the treasury successfully negotiated a 140 to 200 basis point reduction in the effective interest rate (EIR), bringing it down into the single digits.

Management utilized this leverage to prepay high-cost legacy debt, projecting that peak debt-to-EBITDA will remain below 1.5x. The corporate objective is to render the steady-state base business entirely debt-free by FY28, generating a Return on Capital Employed (ROCE) exceeding 50% as the newly installed assets reach optimal utilization.

Corporate Governance and Human Capital

The strategic governance of OneSource is directed by an experienced executive suite and a highly independent board, ensuring alignment with global pharmaceutical standards.

Executive Leadership and Remuneration

The operational pivot is spearheaded by Neeraj Sharma, serving as Executive Director, CEO, and Managing Director. His leadership has been critical in transitioning the company from an R&D-focused entity to a commercial manufacturing powerhouse. His gross remuneration for 2025 was reported at 669.3 Lac. The executive team is further reinforced by Anurag Bhagania (Chief Financial Officer), Biju Mathew (Chief Operating Officer), Bernhard Thurnbauer (Chief Quality Officer), and Jeffrey Wong (Chief Business Officer), alongside Preeti Kalra, who was recently appointed as Head of Human Resources following a leadership transition.

Board Independence and Audit Oversight

Founded by pharmaceutical veteran Arun Kumar (Non-Executive Director), the Board of Directors features significant independent oversight. Key members include Rashmi Harshadrai Barbhaiya (Independent Non-Executive Director, remuneration 10 Lac) and Bharat Shah (Non-Executive Director, remuneration 7 Lac), alongside Claudio Albrecht, Debarati Sen, and Vijay Karwal. In early FY26, the board was expanded with the appointment of Colin Michael Bond as a Non-Executive Independent Director, bringing 15 years of experience as a CFO for multiple international pharmaceutical entities to enhance financial governance.

Demonstrating a commitment to rigorous financial transparency, the board approved the appointment of B S R & Co. LLP as the new statutory auditor in May 2026, replacing Deloitte Haskins & Sells, a move that aligns with standard corporate governance rotations for newly listed, large-cap entities.

Environmental, Social, and Governance (ESG) Framework

In an industry where multinational partners enforce strict supply chain sustainability mandates, OneSource has structurally embedded ESG principles into its operations, evidenced by its inaugural Integrated Report for FY25.

Independent ESG assessments validate these efforts. SGS India provided reasonable assurance on the company's core sustainability indicators. Most notably, the company's EcoVadis rating was upgraded from a baseline of 30 to 64/100, placing it in the Bronze/Silver tier (top 35% globally).

Operationally, OneSource achieved a significant milestone by reaching "Zero Liquid Discharge" status, ensuring no external wastewater is released from its manufacturing units. The energy matrix also improved, with renewable energy consumption rising to 113,219 GJ, commensurate with a sharp decline in non-renewable fuel utilization. Furthermore, the company was recognized for outstanding workplace and contractor safety, receiving the Safety Award from the National Safety Council, Karnataka Chapter, and the Sustainability Excellence Award at the 5th National Bharat CSR & Sustainability Awards 2025. OneSource is also a committed signatory to the United Nations Global Compact, maintaining consistent Carbon Disclosure Project (CDP) scores for water security and climate change.

Capital Markets, Shareholding Structure, and Valuation

Since its market debut, OneSource has attracted intense interest from institutional investors and promoters, reflecting high conviction in the long-term GLP-1 CDMO thesis.

Shareholding Pattern and Promoter Conviction

The equity structure reveals a healthy balance of insider ownership and institutional float.

A critical signaling mechanism occurred in January 2026, during the depths of the Q3 FY26 financial trough. Entities within the promoter group executed creeping acquisitions via open market purchases. Tenshi Pharmaceuticals Private Limited acquired 275,000 shares across multiple sessions, and Pronomz Ventures LLP acquired 33,906 shares, cumulatively increasing the promoter group's stake from 29.93% (December 2025) to 30.48%. This aggressive insider buying during a period of short-term financial pressure underscored the promoters' confidence in the imminent resolution of regulatory delays and the impending surge in GLP-1 commercialization.

Valuation Perspectives and Peer Benchmarking

However, institutional analysts apply forward-looking sum-of-the-parts (SoTP) methodologies to capture the premium attached to the DDC and biologics moats.

When benchmarked against prominent Indian pharmaceutical and CDMO peers such as Gland Pharma, Divi's Laboratories, and Cohance Lifesciences, OneSource provides the most direct, "pure-play" equity exposure to the GLP-1 megatrend. While large generic pharmaceutical companies typically exert downward pricing pressure on CDMOs, the severe global shortage of specialized fill-finish capacity for complex auto-injectors provides OneSource with unprecedented pricing power, insulating its margins.

Brokerage target prices reflect this scarcity premium. Based on SoTP valuations heavily weighted toward the DDC segment—valued in isolation at approximately ₹1,400 per share by some models—and projected FY27/FY28 EBITDA, analyst price targets range from ₹2,049 (JM Financial) to ₹2,200 (ICICI Securities), reaching as high as ₹2,529 (DAM Capital). With the stock trading in the ₹1,500 to ₹1,600 range in mid-2026, the equity is perceived to offer substantial upside potential as the $100 million capacity expansion translates directly into commercial revenue.

Strategic Outlook and Conclusion

The strategic roadmap for OneSource Specialty Pharma Ltd. is predicated on the flawless execution of its capacity expansion and the unwavering maintenance of its regulatory compliance record.

The corporate objective is explicitly defined: management has resolutely reaffirmed its guidance to achieve $400 million in organic revenue with a 40% steady-state EBITDA margin by FY28. This trajectory is supported by the DDC segment alone, which is projected to scale to approximately $187 million, effectively comprising half of the corporate topline. The inherent fungibility of the newly installed cartridge lines allows the company to seamlessly pivot between various batch sizes and complex peptide formulations (e.g., transitioning to generic tirzepatide or other molecules upon patent expiry), providing operational agility.

While the GLP-1 generic rollout—expanding from India and Canada into Brazil, Saudi Arabia, and the broader MENA region—provides the medium-term growth catalyst, the biologics division serves as the high-value, long-term wildcard. As macroeconomic and geopolitical forces, particularly the U.S. BIOSECURE Act, compel Western pharmaceutical entities to restructure their supply chains, OneSource’s fully integrated mammalian and microbial capabilities in Bengaluru are perfectly positioned to absorb this redirected commercial manufacturing volume.

In conclusion, the meticulous consolidation of diverse, high-barrier-to-entry manufacturing assets has engineered a CDMO with a unique technological moat. The financial volatility of Q3 FY26 acted as a rigorous stress test, ultimately proving that while regulatory timelines can temporarily defer revenue recognition, the structural demand for specialized fill-finish capacity remains unyielding. For the global pharmaceutical supply chain, OneSource Specialty Pharma Ltd. has evolved into an indispensable partner, positioned at the nexus of the GLP-1 therapeutic revolution and the geographic realignment of biopharmaceutical manufacturing.